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In this doctoral project we have examined the biological effects of Calanus oil in a mouse 
model of obesity. Calanus oil is extracted from the marine copepod Calanus finmarchicus and 
is one of the richest sources of poly-unsaturated fatty acids in nature.  
C57BL/6J mice were given a high-fat diet (HFD) over a 27 wk period in order to induce 
obesity, which was reflected in deposition of considerable amounts of fat in the abdominal 
cavity and liver. In mice receiving HFD supplemented with a small amount of Calanus oil 
(1.5%) fat accumulation was significantly less, despite no difference in food intake between 
the groups. Obesity was also associated with increased expression of genes (mRNA level) 
coding for pro-inflammatory molecules, as well as macrophage infiltration in adipose tissue, 
indicative of a local (low-grade) inflammation. Moreover, insulin sensitivity was impaired as 
documented by reduction in glucose tolerance. These obesity-induced alterations were clearly 
antagonized by dietary Calanus oil, irrespective of whether it was given from the onset of the 
feeding period or after obesity was established. Another important finding was that wax ester 
from Calanus oil (i.e. the pure lipid component of the oil, devoid of antioxidants and other 
bioactive substances) was as effective as crude Calanus oil for obtaining these beneficial 
effects, and the efficacy of wax ester in producing the anti-obesity effect was even stronger 
than that of the clinically used ethyl esters of purified EPA and DHA. Finally, the increase in 
blood pressure which occurred when obese C57BL/6J mice were challenged by angiotensin II 
infusion was virtually abolished in mice that had been pre-treated with dietary Calanus oil. 
Dietary Calanus oil also antagonized the reduction in body and organ weights associated with 
angiotensin II infusion.  
Collectively, these findings support the notion that low-grade inflammation in adipose tissue 
is the link between obesity and insulin resistance, and that reduction of visceral and ectopic 
fat mass by Calanus oil supplementation is an obvious strategy for targeting the inflammatory 
network. The capacity of dietary Calanus oil to antagonize angiotensin II-induced 
hypertension should also be ascribed to the anti-inflammatory action of the oil, both in the 









1. Obesity epidemic and obesity –related metabolic disorders 
 
In the last 20 years the world has witnessed an alarming increase in obesity (1). This global 
obesity pandemic is the leading cause for the soaring rates of metabolic diseases (2). Today 
obesity (defined as a body mass index above 30) is  prevalent in more than 34% of the adult 
population in the United States (3). However, the condition is on an alarming rise also in the 
developing world,  along with the adoption of a western life style (4). According to the World 
Health Organization (WHO) 1.4 billion adults are overweight worldwide, and 500 million are 
obese. In near future these numbers are expected to rise unless effective actions are taken to 
prevent the development (5). 
The current rise in human obesity is primarily linked to increased energy intake and decreased 
energy expenditure, resulting in excess fat deposition in adipose tissue (6). There is 
considerable evidence indicating that obesity is a contributing factor for  all major metabolic 
disorders, such as insulin resistance, diabetes and fatty liver disease, which in combination 
with cardiovascular disease and hypertension are collectively termed as metabolic syndrome  
(7), cardio metabolic risk (8) or multiple risk factor clustering syndrome (9). Hence, there is a 
growing interest in the role of adipose tissue in the development of  these  pathologies (10). 
Epidemiological studies show that visceral fat mass is more closely correlated with obesity-
associated pathology than over all adiposity (11). This includes the development of local and 
systemic chronic low-grade inflammation, characterized by increased infiltration of immune 
cells into adipose tissue and increased production and subsequent secretion of pro-
inflammatory factors into the circulation (12). 
 
1.1 Low grade inflammation in obese adipose tissue 
 
Obesity, in particular abdominal obesity, is associated with a chronic local low-grade 
inflammation (6, 13, 14). In this process the enlarged/expanded adipocytes start to secrete pro-
inflammatory cytokines (TNFα, IL-6, and IL-1β) and chemokines, such as monocyte chemo-
attractant protein-1(MCP-1) (15). Macrophage infiltration occurs after initial rolling and 
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attachment of monocytes to activated endothelial cells. These monocytes then extravasate 
through the endothelial cell layer and differentiate into macrophages. Weisberg et al. (16) 
showed that chemokine C-C motif ligand -2 (CCL2) and its receptor, Chemokine receptor -2 
(CCR2) play important roles in macrophage chemotaxis. At the onset of  an inflammatory 
process, macrophages that are usually present in the adipose tissue switch from an anti-
inflammatory (M2) state to a pro-inflammatory (M1) state (17). Cross-talk between adipocytes, 
macrophages, and endothelial cells may aggravate the inflammatory state, resulting in 
increased secretion of pro-inflammatory cytokines (adipokines) and chemokines, as well as 
angiogenic factors. These factors could cause local and/or systemic insulin resistance in a 
paracrine and/or endocrine fashion, respectively, and might also induce local angiogenesis. 
More than 90% of M1-type macrophages are localized to dead adipocytes and form so-called 
"crown-like structures" (CLS), which is a characteristic immune-histological picture from 
adipose tissue both in obese mice and humans (18). 
Numerous studies have shown that hypoxia and nutrient excess are the two main triggering 
factors for inflammation in adipose tissue (6, 19, 20). In response to nutrient excess adipocytes 
expand and become hypertrophic. At the same time the distances between the blood bearing 
vessels increase and oxygen diffusion becomes insufficient (21), leading to local hypoxia. 
Thus, adipose tissue of obese individuals show decreased blood flow, increased 
vasoconstriction and reduced capillary density, compared to non-obese adipose tissue (20). 
Hypoxia in the adipose tissue can also play a role in exacerbating pro-inflammatory cytokines 
and chemokines secretion  by activating c-Jun N-terminal protein kinase 1 (JNK1) and 
IkappaB kinase/nuclear factor kappa B (IKK/NF- κB) pathways (13). 
Philipp Scherer and co-workers (22) have documented increased interstitial fibrosis in white 
adipose tissue (WAT) during the development of obesity, which may reduce extracellular 
matrix (ECM) flexibility and decrease the tissue plasticity, ultimately leading to adipocyte 
dysfunction. Abnormal collagen deposition which is a hallmark of fibrosis development in 
adipose tissue,  is closely associated with tissue inflammation and characterized by infiltration 
of macrophages and many other immune cells (23). It has been reported that hypoxia inducible 
factor-1(HIF1α) is induced in response to fat pad expansion and induction of hypoxia. Under 
these conditions an entire set of “fibrotic response” genes are dramatically up-regulated, and  
classically activated pro-inflammatory M1 macrophages are attracted by dead adipocytes, 




















1.2 Obesity and insulin resistance  
 
Secretion of pro-inflammatory cytokines from obese adipose tissue leads to the development 
of a systemic inflammatory response which may impair peripheral organ function, including 
skeletal muscle, heart and vasculature (24, 25). In the face of adipose tissue inflammation and 
fibrosis (as described above) the large (“fatter”) adipocytes becomes dysfunctional with 
increased lipolytic activity. This response leads to increased release of free fatty acids (FFA) 
and ectopic fat deposition, which is believed to play a central role in the development of 
peripheral insulin resistance in both animals and humans (26, 27). Thus, elevated FFA supply 
and ectopic lipid deposition can inhibit insulin-stimulated glucose transport through activation 
of various protein kinases (PKC, IKKβ and JNK) and attenuate expression of genes that are 
involved in mitochondrial oxidative phosphorylation , such as PPARγ co-activator‑1 (PGC‑
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1). Inflammatory cytokines, such as TNFα, impairs insulin signaling, in part by inhibiting 
serine phosphorylation of insulin receptor substrate-1 (IRS-1) (28, 29), but also by inhibition of 
the insulin-regulated glucose transporter 4 (GLUT4) through activation of mitogen activated 
protein kinase kinase kinase kinase-4 (MAP4K4) and JNK kinases (27, 28).  
Finally, it is believed that endoplasmic reticulum (ER) stress occurs during excess influx of 
nutrients, as well as during hypoxia, leading to activation of the unfolded protein response 
(UPR) (30). Studies of insulin action on cultured rat  liver cells show that increased activation 
of UPR leads to increased c-Jun N-terminal kinases (JNK) activity and Ser307 
phosphorylation of  IRS-1(31), linking ER stress and UPR up-regulation to insulin insensitivity 
and inflammation. It is also known that UPR increases IKKβ, which stimulates pro-
inflammatory pathways (30, 32) , all leading to increased inflammation and insulin resistance. 
Combination of obesity and insulin resistance often leads to the development of type 2 
diabetes mellitus (33, 34), which is manifested by decreased insulin-stimulated glucose uptake 
and metabolism in skeletal muscle and adipose tissue, impaired suppression of hepatic 
glucose output (28, 35) and high levels of stored lipids in skeletal muscle. 
 
1.3 Obesity and cardiovascular disease  
 
The higher prevalence of cardiovascular disease in obese individuals associated with the 
increased frequency of various well known risk factors like hypertension, diabetes and 
dyslipidemia (36). However, abdominal obesity with elevated production of pro-inflammatory 
adipocytokines and dysfunction of adipose tissue (described above) are key processes linking 
obesity to cardiovascular diseases, and are the fundament for the so-called “adipo-
cardiovascular axis” (37). Hence, abdominal obesity is regarded perhaps as the most serious 
new risk factor for metabolic and cardiovascular complications.  
Many studies have demonstrated that isolated obesity in human subjects is associated with 
abnormal diastolic function (38), whereas impairment of systolic function is not consistently 
observed (39-41). In humans, evidence suggests that obesity-related cardiomyopathy includes 
left heart remodeling (i.e., left atrial dilatation and left ventricular (LV) hypertrophy) as well 
as abnormalities in left ventricular contractile and relaxation functions (38). Reduced LV 
systolic function has also been demonstrated in several animal models of obesity (42-45), except 
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for some studies in diet-induced obese rats, which showed an unchanged or mildly reduced or 
systolic function (46, 47). Results from our own research group showed that high-fat diet 
enriched with sucrose resulted in reductions in both systolic and diastolic function in mice, as 
well as a marked concentric hypertrophy of the heart (48). In addition, high-fat feeding results 
in a marked increase in myocardial oxygen consumption (due to increased oxygen cost for 
basal metabolism and excitation-contraction coupling) and a significant reduction in 
contractile efficiency (49).  
 
1.4 Obesity and hypertension 
 
 An association between obesity and hypertension is well established in humans (50, 51). A 
number of mechanisms have been suggested to be involved, including activation of the 
sympathetic nervous system, sodium retention, RAS activation, increased secretion of leptin 
and other neuropeptides, as well as insulin resistance and inflammation (52). Damage and 
dysfunction of the vascular endothelium is an underlying factor in the pathogenesis of 
hypertension, and in the context of this thesis we will briefly mention how obesity-related 
insulin resistance and inflammation may impact on the endothelial function and produce 
hypertension.  
Nitric oxide (NO), which is produced in the vascular endothelium from the amino acid L-
arginine by the enzymatic action of the endothelial nitric oxide synthase (eNOS), plays a 
central role in vascular reactivity. Under normal conditions insulin phosphorylates and 
activates eNOS (via phosphorylation of IRS-1 and subsequent activation of PI 3-kinase, PDK-
1 and Akt (53), resulting in increased NO production. In addition, the MAP kinase branch of 
insulin signaling causes secretion of vasoconstrictor endothelin-1 (Fig. 2).  
The PI-3 kinase pathway is down-regulated, however, in insulin resistant states, leading to 
impairment of NO synthesis, whereas the MAP kinase pathway, on the other hand, remains 
unaltered. As a result, an imbalance between vasodilator and vasoconstrictor actions is 
established in favor of vasoconstriction (54). In addition, elevated serum levels of glucose and 

























A number of other biologically active molecules are also derived from obese adipose tissue 
(including perivascular adipose tissue) such as reactive oxygen species (ROS), vascular 
endothelial growth factor, plasminogen activator inhibitor-1, thromboxane A2  and acute 
phase reaction proteins (serum amyloid A proteins, C-reactive protein) (58, 59). These 




















1.5 Protein (O-GlcNAcylation) modification in obesity 
 
Protein O-GlcNAcylation is a protein post translational modification (PTM) in which a single 
beta- acetyl-N-glucosamine moiety is attached to serine and threonine through formation of 
an O-linked ester, quite similar to protein phosphorylation. The level of protein O-
GlcNAcylation can be regulated by glutamine: fructose-6-phosphate aminotransferase 
(GFAT), the rate-limiting enzyme in the hexosamine biosynthesis pathway or by the enzymes 
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catalyzing the addition or removal the O-GlcNAc moiety from proteins, i.e. O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA) (60).  
 The nature of this PTM is controversial with respect to its impact on health, i.e. increased 
protein O-GlcNAcylation is linked to insulin resistance (61, 62), but it has also been shown to be 
cardioprotective when induced before a challenge such as ischemia-reperfusion, or oxidative 
stress whereas inhibition of O-GlcNAc formation decreases myocardial cell survival (63, 64). It 
is generally agreed that that increased cellular O-GlcNAcylation lowers the phosphorylation 
of IRS1 Tyr608, decreases  AKT activation and consequently decrease glucose uptake via 
GLUT4 (65). By this mechanism, the nutritional status of the cell is intimately linked with the 
level of O-GlcNAcylation, nutrient processing, and insulin signaling (66). 
An increase in protein O-GlcNAcylation has been shown to reduce inflammation and 
cytokine expression in relation to acute vascular injury (67)  and has also been shown to 
preserve vascular reactivity in vessels exposed to elevated levels of TNFα (68). The complete 
mechanism by which enhanced protein O-GlcNAcylation leads to a reduction in inflammation 
is unknown. Recent studies have suggested, however, that O-GlcNAc may act on transcription 
factors such as NFκB, to prevent their activation (69, 70). In addition, it may reduce or mitigate 
the effects of ER stress, preventing further cell damage and apoptosis (71). 
On the other hand O-GlcNAcylation has been shown to contribute to adverse effects of 
diabetes on the heart when  glucose metabolism is increased via the hexosamine biosynthesis 
pathway (HBP) (72). In addition, O-GlcNAcylation impaired cardiomyocyte hypertrophy and 
cell signaling pathways in diabetic models (72). Lima and co-workers (2012) reported 
increased OGlcNAcylation in the vasculature in diabetes (73, 74), which could explain vascular 
dysfunction associated with arterial hypertension and diabetes (60). 
 
2. Polyunsaturated fatty acids (PUFAs) and disease prevention 
 
Polyunsaturated fatty acids (PUFAs) are fatty acids that contain more than one double bound 
in their backbone. The two main PUFA families, omega-3 and omega-6, have the final C-C 
double bond in the n-3 and n-6 position, respectively, and they are classified as essential fatty 
acids, since they cannot be synthesized in sufficient amounts and therefore need to be 
obtained via diet (75-77). These fatty acids have important biological activities in cell function 
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and growth, reproduction (78) and regulation of gene expression (79). Western diets typically 
contain high n−6/n−3 PUFAs ratio (15:1 to 16.7:1), which could promote inflammation and 
mediate of many chronic diseases, such as coronary heart disease, rheumatoid arthritis, 
obesity, diabetes, cancer, and mental illness (80, 81). Moreover, there is evidence showing that a 
high content of n-6 PUFAs in the diet, comparative to n-3 PUFAs, is a predisposing factor for 
obesity (82). Therefore, an optimal balance between n−6 PUFA/n−3 PUFA intake has been 
considered to be of importance when recommending PUFA supplementation for decreasing 
the risk of these chronic diseases (80, 83).Today the recommended intake of the essential n-3 
and n-6 PUFAs ratio is 1:4-1:5 (75).  
Linoleic acid (18:2, n−6) is a representative of the n−6 PUFA family. It is very abundant in 
the western diet, and is the precursor of arachidonic acid (20:4, n−6) (76). Alpha linolenic 
(18:3, n−3), which is found in vegetable oils, is the common precursor of  eicosapentaenoic 
acid (EPA, 20:5, n−3) and docosahexaenoic acid (DHA,22:6, n−3) which are the typical 
marine n-3 PUFAs. Both n-3 and n-6 PUFAs can compete for the same enzyme for elongation 
and desaturation in the metabolic pathway (Fig. 4). So, if there is an excess of one fatty acid 
family it can interrupt the metabolism of the other (84).Therefore, an excessive intake of 



























2.1 Anti-inflammatory action of n-3 PUFAs  
 
Both animal and human studies have shown that supplementation of EPA and DHA may be 
protective against obesity, and may lessen weight gain in already obese animals and humans 
(87). Thus, in rats fed with high lipid diets combined with n-3 PUFAs (88, 89) the amount of 
visceral (epidydimal and/or retroperitoneal) fat was reduced in a dose-dependent manner (90). 
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The reduction in visceral fat was seen in some studies without changes in energy intake (88, 91, 
92) while other studies reported a significantly decreased food intake (93, 94).  
One of the advantages with increasing n-3 PUFAs in the diet is related to its anti-
inflammatory action (85). There is a variety of molecular mechanisms underlying the anti-
nflammatory action of n−3 PUFA, namely altered synthesis of eicosanoids (prostaglandins, 
leukotrienes), activation or inhibition of nuclear receptors (e.g. peroxisome proliferator- 
activated receptor γ [PPARγ], liver X receptors) and alterations of membrane lipid rafts (95, 96). 
There is no evidence for a selectivity of PPARγ for n−3 PUFA (97) regardless of anti-
inflammatory effects of PPARγ agonists in obese animals and humans (98, 99). Other suggested 
mechanisms behind n-3 PUFA-mediated reduction in inflammatory activity include inhibition 
of the pro-inflammatory NFkB signalling pathway, increased production of pro-resolving 
mediators (such as resolvins, protectins or maresins) (100) and activation of the novel G-protein 
coupled receptor (GPR) 120 (101, 102). 
 
2.2 n-3 PUFAs and cardiovascular diseases 
 
For many years it has been clear that dietary inclusion of  marine oils rich in  PUFAs exerts 
anti-atherogenic actions in human coronary heart disease  (103-105). The beneficial effects of n-3 
PUFA on the cardiovascular system might result from their effects on some modifiable risk 
factors such as plasma lipids (77, 106, 107)  and blood pressure (108-110). A meta-analysis by Morris 
et al. demonstrated a significant and dose-dependent hypotensive effect of fish oil in patients 
with hypertension (111). The cardioprotective effects of n-3 PUFA are supported by a number 
of experimental studies in cell culture (112) and animal studies (108, 113), as well as human trials 
(85, 114). Population studies have recommended that regular fish meals (especially fat fish) 
could protect against many cardiovascular events (106, 115). This effect has been associated with 
the high content of n-3 PUFA. n-3 PUFA in the form of fish oil or its purified constituents, 
EPA and  DHA has been shown to be inversely related to cardiovascular mortality (114, 116, 117). 
Thus, numerous studies have reported that  n-3 PUFA lowered  risk factors for heart failure, 
such as obesity, type II diabetes, insulin resistance, hypertension and inflammation (118-122). 
The mechanism by which n-3 PUFA reduces blood pressure is still to be determined. 
However, dietary supplements with PUFAs have  been shown to prevent hypertension in 
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various animal models by  increasing nitric oxide production , decrease vascular wall 
thickness in the coronary arteries  as well as blunting renin-angiotensin-aldosterone system 
and modulation of calcium release in smooth muscle cells (108, 123, 124). Alterations in vascular 
reactivity and reduction in Serum thromboxane A2 (TXA2) level upon fish oil 
supplementation has been suggested to possible mechanism for the hypotensive effect (113). A 
few studies have suggested that n-3 PUFA influences blood pressure through an interaction 
with angiotensin II (125). In addition, anti-inflammatory  and blood pressure-lowering 
properties of these fatty acids might provide protection of the cardiovasculature (85). Thus, 
administration of n-3 PUFA lowered blood pressure in AngII -induced hypertensive rats (126). 
Eicosapentaenoic acid (EPA) has been shown to depress vascular responses induced by 
exogenous Ang II in rabit  (127). In humans moderate doses of fish oil could reduce vascular 
resistance in response to infusion of Ang II (128, 129). 
 
3. Calanus oil-a novel marine oil 
 
Calanus oil is extracted from the marine copepod Calanus finmarchicus, which is the most 
abundant crustacean and one of the dominating food sources for fish in the North Atlantic 
(130). The copepod is small (3-4 mm long) and grows in large volumes (200-400 tons) in the 
sea masses,  providing approximately 50% of annual biomass production on the North 
Atlantic (131). The copepod nourishes itself on various forms of phytoplankton, and during the 
spring and summer months it stores large amounts of energy in the form of oil, which can 
account for as much as 50% of its dry weight. During the fall and winter the copepod sinks to 
depths from 500-2500 m where it “hibernates” until the nest spring when it returns to surface 
waters. Calanus finmarchicus does not accumulate environmental toxins, as it is situated at a 
very low trophic level of the marine ecosystem. Therefore, the oil can be used in its natural 
form, avoiding cleaning processes, which is normally required for marine oils from fish and 
sea mammals (132). 
Like other marine oils, Calanus oil is very rich in the essential marine n -3 fatty acids EPA 
and DHA (Table 1). Calanus oil also contains the essential fatty acid stearidonic acid (SDA, 
18:4, n-3) and other long chain mono-unsaturated fatty acids (MUFA), such as gondoic acid 
(20:1 n-9) and cetolieic acid (22:1 n-11) (133). Table 1 shows the composition of Calanus oil 






The fatty acids in Calanus oil  is mostly bound as monoesters (also known as wax esters), 
where the fatty acids are linked to long-chain unsaturated alcohols. In krill the larger part of 
the fatty acids are bound in phospholipids, while in in fish and marine mammals they are 
bound as triglycerides. 
Calanus oil also contains proteins, vitamins, minerals, phytosterols, as well as a high amount 
of the antioxidant astaxanthin. The astaxanthin is giving the oil its characteristic red color, and 
it is one of the strongest anti-oxidant found in nature (134). In addition to protecting the stored 
lipid in calanus finmarchicus (135), astaxanthin is suggested to have potential health benefits in 
cancer, chronic inflammatory and  neurodegenerative conditions, as well as in cardiovascular- 






Lipids of marine origin have received considerable attention, because of their beneficial 
effects on cardiovascular health (anti-inflammatory, anti-thrombotic, anti-arrhythmic, hypo-
lipidemic and vasodilatory action). Oil from the marine copepod Calanus finmarchicus has a 
unique composition, and in a recent study, Eilertsen et al.(137) showed that dietary 
supplementation with Calanus oil was able to decrease plaque formation in apoE-deficient 
mice. 
This doctoral project was designed to further examine the biological effects of Calanus oil, 
using a mouse model of diet-induced obesity. The specific objectives were:  
1. to investigate the effect of Calanus oil on diet-induced (abdominal) obesity and its 
metabolic disorders, using both a preventive and a therapeutic approach 
2. to determine if purified wax ester from Calanus oil could provide the same effects as 
crude Calanus oil, i.e. whether potential beneficial effects of the lipids remain in the 
absence of other biologically active constituents of the oil  
3. to determine the impact of Calanus oil on hypertension and cardiac remodeling in diet-
















1. Animals and dietary regimens 
 
In this project we used a mouse model of diet-induced obesity. The animals were housed at 
Department of Comparative Medicine (Faculty of Health Sciences, UiT The Arctic University 
of Norway) and treated according to the guidelines on Accommodation and Care of 
Laboratory Animals Used for Scientific Purposes Formulated by the European Convention for 
the Protection of Vertebrate Animals. All procedures were approved by the local authority of 
the National Animal Research Authority in Norway.  
Obesity was induced by feeding male C57BL/6J mice a lard-based high-fat diet (HFD) (Test 
diet 58V8, corresponding to the original D12451 from Research Diets) containing 18, 36 and 
46% of energy from protein, carbohydrate and fat, respectively. Because of it relatively high 
content of carbohydrate this diet resembles a typical “Western” type diet. Lean control mice 
were given normal chow containing 18, 72 and 10% of energy from protein, carbohydrate and 
fat (CTR, no. 58Y2, Test Diet; IPS Limited). The specification sheets of the diets are shown 
in the Appendix.  
It should be noted that addition of Calanus oil (1.5 g/100 g) to the HFD was compensated for 
by the removal of the same amount of lard, so that the total fat content was similar and the 
diets remained isoenergetic. It is also worth noticing that the amount of Calanus oil was only a 
fraction of that used in similar studies reported in the literature, and there was no indication 
that the animals did not like the food, since we the food intake was the same for the groups 
receiving HFD with and without Calanus oil. 
C57BL/6J mice is a common inbred laboratory mouse strain, meaning that the genotype of the 
individuals within this strain is nearly identical, which will reduce individual variation and 
increase the likelihood for detecting significant differences between experimental groups. In 
addition, animal studies have the advantage that they can be performed under strictly 
controlled laboratory conditions (temperature, humidity etc.), which also will reduce 
individual variability. C57BL/6J mice are regarded obesity-prone, and during high-fat feeding 
they develop many of the same characteristics as found in human obesity, such as elevated 
plasma glucose, insulin resistance and ectopic fat deposition (138, 139). This mouse strain, 
therefore, is regarded as a suitable model for studying pathophysiological consequences of 
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obesity. Results obtained in mice should, however, be extrapolated to humans with caution, 
because humans are quite heterogeneous genetically, and the effect of a certain treatment 
could vary considerably – also because of differences in e.g. digestive physiology and 
metabolic regulation. 
 
2. Analytical methods 
 
2.1 Glucose tolerance test 
 
The global incidence of obesity and type 2 diabetes requires new therapies for treatment. The 
diet-induced obese mouse model has been metabolically well characterized, and several 
methods are used for assessment of glucometabolic control in this model. The oral glucose 
tolerance test (OGTT) is considered the most physiological test, since it mimics the normal 
route by which carbohydrates are ingested. Following absorption from the intestinal tract and 
uptake in the splanchnic and systemic circulation, blood glucose concentration increases. The 
elevation of blood glucose is in turn a major stimulus for insulin release from the pancreas. 
The passage of carbohydrates through the first part of the intestine stimulates the release of 
the gut hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like 
peptide-1 (GLP-1), which in turn augment the beta cell sensitivity to glucose, increasing the 
production of insulin (140, 141). 
During an OGTT glucose is administered by means of a gavage tube. This procedure can 
imply stress to the animal and unreliable glucose values, and for this reason we used a simple 
intra-peritoneal glucose tolerance test (IPGTT). Glucose was injected intra-peritoneally, and 
the mice were placed in a restraining cage, allowing for repeated blood sampling from a small 
incision of the saphenous vein. The gut effect (i.e. glucose-stimulated GIP and GLP-1 release) 
is however lost by the use of this method. 
The hyperinsulinemic –euglycemic glucose clamp technique provides an absolute index of 
insulin sensitivity. It is used mainly for humans and large animals, but in recent years it has 
also been adopted for mice (142, 143). It is a relatively time-consuming and requires good 




2.2 Fat depots in abdomen 
 
Adipose tissue was for many years regarded merely as a passive energy store, but our present 
understanding is that adipose tissue has important endocrine functions, by secreting    several 
immune-modulatory proteins (adipokines). Moreover, obesity is associated with a local low-
grade inflammation in adipose tissue, as reflected by an increased expression of genes coding 
for pro-inflammatory adipokines and diminished expression of anti-inflammatory adipokines. 
The resulting adipokine imbalance is suggested to play a key role in the development of 
obesity-related metabolic dysfunction and cardiovascular disease (144).  
Local hypoxia has been suggested as the triggering event for adipokine expression in obesity, 
due to the fact that diffusion of oxygen becomes limited as the adipocytes grow in size (145, 
146). We were therefore interested in finding out whether Calanus oil could prevent fat 
deposition (adipocyte expansion) during high-fat feeding. Visceral or intra-abdominal fat 
(including omental, mesenteric, perirenal and perigonadal fat) is considered a major source of 
pro-inflammatory adipokines, and abdominal obesity is more closely related to metabolic 
dysfunction and cardiovascular disease than general obesity (11, 147). In addition, it has been 
reported that insulin sensitivity in rodents can be improved by surgical removal of epididymal 
(eWAT) and perirenal (pWAT) (148, 149). In our hands, we found it relatively easy to identify 
and dissect out pWAT and eWAT, and that we could determine the mass of these with high 
accuracy. Perirenal fat mass was normally chosen as an indicator of abdominal obesity. In 
addition, this depot was used for immune-histological examinations. 
 
2.3 Hepatic triacylglycerol content 
 
In addition to adipose tissue, the liver is affected by obesity, and inflammatory gene 
expression increases in liver with increasing adiposity (150), creating an inflammatory response 
similar to the adipose tissue inflammation that follows adipocyte lipid accumulation. The pro-
inflammatory cytokines activate a number of immune cells present in liver, in particular 
Kupffer cells, which are believed to participate in hepatic inflammation (150, 151). It was 
therefore of interest to determine whether high-fat feeding resulted in increased 
triacylglycerol content in the liver and even more pressing, whether dietary Calanus oil could 
the attenuate any hepatic fat deposition. 
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Triacylglycerol content in liver tissue can be determined by biochemical or histological 
techniques. We used a biochemical method based on enzymatic degradation of the 
triacylglycerol molecules to yield free fatty acids and glycerol. Since the amount of fat may 
vary depending on the region where the biopsy is taken, we homogenized a relatively large 
piece of liver tissue. Lipids were extracted from aliquots of this homogenate, using the 
method of Folch (152). The extracted lipids were dried and emulsified in a special buffer before 
the chemical analysis (measurement of glycerol). 
 
2.4 Immunohistological investigations  
 
In our studies we identified macrophages by staining with the antibody F4/80 which is an 
extracellular antigen (glycosylated proteoglycan) on murine macrophages (153) similar to 
human EMR1 (EGF-like module-containing mucin-like hormone receptor-like 1) which is 
encoded by the EMR1 gene. The F4/80 marker is used as a general macrophage marker, but 
CD11c (M1) or MGL-1 (M2) can differentiate between M1 and M2 sub populations (17, 154). 
Preferably we would have used one or several of those more specific antibodies. However, 
using F4/80 antibody dead adipocytes surrounded by macrophages (so-called crown like 
structure (CLS)) appeared clearly in our immunohistochemistry sections, and therefore we 
considered the choice of the F4/80 antibody to be acceptable for our analysis. 
 
2.5 Real time quantitative PCR (qPCR) 
 
Real-time qPCR is an important tool in gene expression analysis and has gained acceptance 
because of its rapidity and sensitivity as compared to the traditional method for quantitative 
measurement of gene expression, such as Northern blotting. Both absolute and relative 
quantification of gene expression can be analyzed by Real-time qPCR. It is important to 
choose a suitable gene for use as a reference or housekeeping gene when performing relative 
quantification of the expression of a target gene. The expression of the housekeeping genes 
should not vary in response to the experimental intervention but, unfortunately, housekeeping 
genes can still vary despite being constant in a given cell-type or experimental condition 
(155).Therefore, in our study we used the geometric mean of the three best out of a selection of 
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5-6 housekeeping genes, instead of using one reference gene as recommended by 
Vandesompele et al.(155). 
 
2.6 Blood pressure measurement 
 
Blood pressure was measured in conscious animals using the tail-cuff method (Kent 
Scientific, CODA- Torrington, CT, USA). This Non-invasive tail-cuff blood pressure device 
utilizes Volume-Pressure Recording (VPR) and is regarded as a valuable tool for measuring 
systolic and diastolic blood pressure in high-throughput experimental designs. Feng et al. (156) 
validated the VPR tail-cuff method by comparison to the more accepted radio-telemetry 
method and concluded that it provides accurate blood pressure measurements over the 
physiological range in mice. Furthermore, this method offers the highest degree of correlation 
with telemetry and direct blood pressure measurements, and it is clearly the preferred tail-cuff 
sensor technology (157). In addition, the methodology requires no surgery, and it is 
significantly less expensive than other blood pressure methods. It should be noted that obesity 
in rodents is not always accompanied by hypertension (158, 159) and in order to get a "window 













3. Study Design  
 
Paper I 
Diet-induced obese mice were obtained by feeding  5–6-week-old C57BL/6J male mice 
(Charles River) a lard based high-fat diet (HFD, no. 58V8, Test Diet; IPS Limited) containing 
18, 36 and 46% of energy from protein, carbohydrate and fat, respectively .There were three 
groups of obese mice: the first receiving the high fat diet (HFD) throughout the whole 27-
week feeding period ; the second receiving the HFD supplemented with 1.5% (w/w) Calanus 
oil from the start and throughout the entire 27-week feeding period (preventive treatment, 
CAP); the third receiving the HFD (without supplementation) for 7 weeks, followed by the 
HFD with 1.5% (w/w) Calanus oil supplementation for the remaining feeding period 
(therapeutic treatment, CAT) (Fig. 5). It is important to note that addition of Calanus oil was 
compensated for by the removal of 1.5 g lard/100 g diet, so that the total fat content was 
unchanged and the diets remained isoenergetic. Body weight was recorded weekly throughout 
the experimental period, while food (energy) intake and glucose tolerance were recorded 
towards the end of the period. Tissue samples for biometric, immunohistochemical, and gene 
expression analysis, as well as blood samples for biochemical analysis, were sampled at 
sacrifice. 
                         




The experimental design followed pattern as in paper I. Again we used 5-6 wk old C57BL/J6 
male mice (Charles River) which were fed an HFD (catalog no. 58V8; TestDiet, IPS Ltd.). 
After 7 weeks, however, the  mice were divided into 3 groups, receiving either HFD alone , 
HFD supplemented with 0.2% (wt:wt) purified EPA + DHA ethyl esters (OMACOR; Pronova 
BioPharma)  or 1% (wt:wt) Calnus oil-derived wax ester (Fig. 6) . The amount of EPA and 
DHA added to the HFD was equivalent to the total content of n–3 PUFAs in the wax ester 
supplemented diet. This dietary regimen was continued for another 20 weeks.  
 
                 
 Fig. 6: Dietary regimen, time course and experimental interventions for paper II. 
 
Paper III 
C57BL/J6 male mice (5-6 week old at the start of the feeding period) were randomly divided 
in two groups, one receiving HFD supplemented with 2% (w/w) Calanus oil (HFD+CAL), 
while the other received no supplementation (HFD). After an initial 8 week feeding period, 
both groups were further sub-divided into two groups, receiving Ang II (Calbiochem, 
Dramstadt , Germany) (1µg/kg/min)  or saline for another two weeks via mini osmotic pumps  
(Alzet mini osmotic pump) (Fig. 7), while on the same dietary regimen. Body weight and 
blood pressure were measured weekly during the initial 8 weeks and 3 days/week after Ang II 
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administration. Tissue samples for biometric, immunohistochemical, and gene expression 
analysis, as well as blood samples for biochemical analysis, were sampled at sacrifice.     
 
             








The main finding of this study was that dietary supplementation with Calanus oil significantly 
reduced body weight gain, abdominal fat deposition and hepatic steatosis in high-fat fed 
C57BL/6J mice. At the same time it improved insulin sensitivity, as determined by a glucose 
tolerance test. It should be noted that these effects were obtained by dietary concentrations of 
n-3 fatty acids which were considerably lower than those reported to attenuate obesity and 
obesity-related abnormalities in previous studies. Calanus oil supplementation also reduced 
adipocyte size, macrophage infiltration and mRNA expression of pro-inflammatory cytokines 
(TNFα, IL-6 and MCP-1) in abdominal fat depots, while mRNA expression of adiponectin 
was increased. Moreover, the effects of Calanus oil were not only preventive, but also 
therapeutic, as the oil proved to be beneficial, regardless of whether supplementation was 
started before or after the onset of obesity and glucose intolerance. Although this study did 
not focus on the mechanism(s) by which Calanus oil provides its beneficial effects, we 
anticipated that they could be ascribed to the n-3 fatty acids EPA and DHA and/or 




A major aim of the second study was to find out if dietary supplementation with Calanus oil-
derived wax ester could mimic the biological effects of crude Calanus oil. In addition, we 
wanted to compare the effect of wax ester with ethyl esters of purified EPA and DHA. Thus, 
we used C57BL/6J mice which received a high-fat diet, starting supplementation  with  wax 
ester or  EPA and DHA ethyl ester  after obesity and glucose intolerance was established. The 
results obtained with wax ester supplementation was almost identical to those obtained with 
crude Calanus oil in study I, i.e. reduced body weight gain, reduced abdominal fat and hepatic 
steatosis, while glucose tolerance was improved. In adipose tissue, macrophage infiltration 
was significantly reduced, mRNA-expression of proinflammatory genes (TNFα, IL-6 and 
MCP-1) downregulated and adiponectin expression upregulated. By comparison, EPA and 
DHA ethyl esters did not significantly affect any of the obesity parameters (body weight gain, 
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abdominal fat or hepatic steatosis) or mRNA-expression of adiponectin. It did, however, 
suppress the expression of pro-inflammatory genes and improved glucose tolerance, although 
not to the same extent as the wax ester supplement. Based on these results we concluded that 
the active component of Calanus oil is confined to its main lipid constituent, namely the wax 
ester. Wax ester had a more clear anti-obesity effect compared to EPA and DHA ethyl esters, 




In this study we tested whether Calanus oil was able to attenuate angiotensin II (Ang II) -
induced changes in blood pressure and cardiac remodeling in diet-induced obese mice. Thus, 
C57BL/6J mice were initially subjected to 8 weeks of HFD with or without 2% Calanus oil. 
Thereafter, animals within each group were randomized for the administration of either Ang 
II (1 μg/kg/min) or saline for another two weeks. Ang II caused a marked elevation in blood 
pressure in mice receiving non-supplemented HFD, while this response was clearly attenuated 
in mice receiving Calanus oil supplementation. Ang II also caused a marked decline in body 
and organ weights in mice receiving non-supplemented HFD, whereas this effect was less 
prominent in mice receiving Calanus oil supplementation. Infusion of Ang II produced 
cardiac hypertrophy and up-regulation of marker genes of both hypertrophy (ANF, β-MHC) 
and fibrosis (Timp1 and Fn-1). This response was however not affected by dietary Calanus 
oil. The mRNA level of fibrotic genes (Col-α1 and Col III-α1, Fn-1) and inflammatory genes 
(TNFα and IL-6) were also up-regulated in the aorta following Ang II infusion, while dietary 
Calanus oil appeared to block the inflammatory response. Interestingly, Calanus oil appeared 
to have a protective effect as fewer mice in the Calanus oil supplimentation group were 
removed due to death/sacrifice than the HFD group receiving Ang II and no oil 
supplementation. Finally, we demonstrated that Calanus oil led to a robust increase in cardiac 
protein O-GlcNAcylation, probably a protective adaptation which, in combination with the 








In this doctoral project we have shown that dietary supplementation with Calanus oil during 
high-fat feeding in mice was able to significantly reduce abdominal as well as ectopic fat 
deposition, which otherwise occurred with non-supplemented high-fat feeding. At the same 
time, obesity-induced low-grade inflammation in adipose tissue, as well as glucose 
intolerance, were attenuated. The same beneficial results were obtained when the diet was 
supplemented with Calanus oil-derived wax ester, indicating that the active component in 
Calanus oil is confined to its lipid constituent. Finally we found that dietary supplementation 
with Calanus oil was able to attenuate hypertension induced by Ang II infusion, as well as the 
accompanying condition of cachexia.  
 
Anti-obesity action of Calanus oil 
 
Beneficial health effects of marine oils have traditionally been ascribed to their content of n–3 
PUFAs, particularly EPA and DHA, and many studies have shown that n–3 PUFAs can 
counteract obesity-related metabolic disturbances (93, 160, 161).Decreased energy intake (93) and 
suppression of lipogenesis (162, 163) are the two proposed mechanisms for the anti-obesity effect 
of n-3 PUFA. Calculations (based on food intake measurements) showed, however, that the 
anti-obesity effect of Calanus oil could not be explained in terms of reduced energy intake. 
Thus, it is more likely that an imbalance between fat deposition and fat mobilization can 
explain the reduced abdominal fat depots in response to intake of Calanus oil. In line with this 
notion, it has been reported that isolated adipocytes from mice given a high fat diet supplied 
with EPA express lower levels of glycerol-3-phosphate dehydrogenase, which is a key 
regulatory enzyme in the process of lipogenesis (164), and it has also been shown that 
administration of EPA suppresses hepatic lipogenesis (162). Hence, it is possible that the active 
component of Calanus oil leads to activation of lipolysis in perirenal fat which overrides 
lipogenesis, thereby explaining the reduction in size of this particular fat depot. It has also 
been reported that astaxanthin, a strong antioxidant found in Calanus oil, can decrease the 
amount of abdominal fat in diet-induced obese mice (165), but in our hands this was not the 




Finally, it should be noted that supplementing the high-fat diet with purified ethyl esters of 
EPA and DHA, matching the total amount of n-3 PUFA in the 1.5% Calanus oil-
supplemented diet did not provide a clear anti-obesity effect, neither in the form of body 
weight reduction nor in reductions of abdominal fat mass or hepatic TAG content. Probably, 
the anti-obesity action of Calanus oil (compared to the purified ethyl esters) depends on its 
content of other omega-3 fatty acids and/or mono-unsaturated fatty acids (gondoic acid and 
cetoleic acid).  
 
Anti-inflammatory- and insulin-sensitizing action of Calanus oil 
 
Calanus oil (as well as wax esters derived from the oil) attenuated the inflammatory response 
in abdominal adipose tissue, which was accompanied by reduced adipocyte size, as well as 
reduced inflammatory gene expression and macrophage infiltration in abdominal fat tissue. It 
is well documented that there is a strong correlation between adipose cell enlargement and 
macrophage (M1) infiltration in the adipose tissue (99, 166). The most accepted theory behind 
this observation is that expansion of adipocytes leads to local hypoxia and activation of 
hypoxia-inducible factor 1-alpha (HIF1α), which in turn leads to up-regulation of pro-
inflammatory genes (6, 22).  
In line with the well-established link between low-grade inflammation in adipose tissue and 
insulin resistance (99, 167), the present study showed that the reduced inflammatory state after 
WE supplementation was accompanied by reduced circulating glucose and insulin  
concentrations, as well as improved glucose tolerance. The inflammatory state was also 
reduced in mice receiving EPA/DHA-supplemented diet, whereas plasma glucose, glucose 
tolerance, and insulin values were only modestly affected. The explanation for this finding is 
not clear, but the markedly lower expression of the insulin-sensitizing hormone adiponectin in 
adipose tissue of the EPA/DHA group might be one explanatory factor. 
 Numerous studies show that dietary PUFAs appear to exert preventive effects on the 
development of insulin resistance and diabetes (168, 169), specifically when compared  with 
saturated fatty acids that promote diabetes development (170, 171). High n-3 PUFA content diet 
results in insulin sensitization due to enhanced stimulation of GPR120 and anti-inflammatory 
effects (101). It has been suggested that n-3 PUFA might interfere with insulin secretion, which 




Antihypertensive and anti-cachexic action of Calanus oil 
 
Administration of Ang II leads to elevated blood pressure, as well as cardiac remodeling. In 
high-fat fed mice we observed, however, that dietary supplementation with Calanus oil 
prevented the Ang II-induced rise in blood pressure. Ang II-induced hypertension, as reflected 
by increased heart weight and increased mRNA expression of hypertropic (ANP, BNP, β-
MHC) and fibrotic genes (Col I-α1 and Col III–α1, TIMP1 and Fn-1) were not influenced by 
Calanus oil supplementation, and therefore the anti-hypertensive action of Calanus oil could 
be related to events at the vascular bed. Of interest, we observed that Calanus oil blunted the 
Ang II-induced increase in Col I-α1 and Col III–α1 mRNA expression in aorta, and it also 
effectively prevented the increase in TNFα and IL-6 expression in this tissue. Thus, it appears 
that dietary Calanus oil prevented the Ang II-induced rise in blood pressure by reducing the 
inflammatory response in the vessel wall.  
Another striking observation in the present study was that acute treatment of diet-induced 
obese mice with Ang II led to a marked decrease in body mass in comparison to saline-treated 
mice and, more importantly, that this effect was generally blunted in mice receiving dietary 
Calanus oil supplementation. Several mechanisms have been implicated for the cachexic 
action of Ang II. Based on studies in rats Brink et al. (173) suggested already in 1996 that Ang 
II infusion produces weight loss through a pressor-independent mechanism that includes a 
marked anorexigenic effect. Cassis et al. (174) reported that low levels of Ang II infusion 
regulate body weight through mechanisms related to increased peripheral metabolism 
(reflected as increased surface temperature), while others have reported an increase in 
mitochondrial uncoupling protein 2 (UCP2) expression in skeletal muscle after Ang II (175). 
In an attempt to further uncover underlying causes for the response to Ang II, as well as the 
beneficial effect of Calanus oil, we examined cardiac tissue for general changes in protein O-
GlcNAcylation. Somewhat surprisingly, we found that dietary supplementation with Calanus 
oil led to a general increase in protein O-GlcNAcylation in heart tissue, but realized that this 
may be viewed as a cardioprotective process, since it mitigated many of the adverse effects of 
Ang II on survival, changes in tissue mass, and the increase in blood pressure that was 
observed in the mice which did not receive Calanus oil. The exact mechanism of the 
cardioprotection afforded by increased O-GlcNAcylation is currently unknown; however, 
38 
 
recent studies have suggested that it may reduce or mitigate the effects of ER stress and 
prevent further cell damage and apoptosis (71). Furthermore, studies on isolated cardiac 
myocytes have indicated that O-GlcNAcylation can limit the development of cardiac 
hypertrophy (72), but this effect was not observed in our model of Ang II-treated obese mice, 























In this doctoral project we have shown that dietary supplementation with Calanus oil during 
high-fat feeding in mice was able to significantly reduce abdominal as well as ectopic fat 
deposition. The treatment significantly reduced the obesity-related low-grade inflammation in 
adipose tissue, while at the same time improving glucose tolerance. Collectively, these 
findings support the notion that low-grade inflammation in adipose tissue is the link between 
obesity and insulin resistance, and that reduction of visceral fat mass by Calanus oil 
supplementation is an obvious possibility for targeting the inflammatory network. Finally, 
dietary Calanus oil can antagonize Ang II-induced hypertension and cachexia, an effect that 








































































































































































































































































































































































































































































































































Fiber (max), % 4.7






Lysine, % 1.38 Magnesium, % 0.05
Manganese, ppm 55
Methionine, % 0.49














Vitamin A, IU/g 3.8
Vitamin B-12, mcg/kg 9
Vitamin D-3 (added), IU/g 0.9
Vitamin E, IU/kg 49.3
Vitamin K (as menadione), ppm 0.48
Zinc, ppm 34
Niacin, ppm 28







N U T R I T I O N A L   P R O F I L E 1
1.  Based on the latest ingredient analysis 
information.  Since nutrient composition of 
natural ingredients varies, analysis will 
differ accordingly.  Nutrients expressed as 
percent of ration on an As-Fed basis 
except where otherwise indicated.  
2.  Energy (kcal/gm) - Sum of decimal 
fractions of protein, fat and carbohydrate x 
4,9,4 kcal/gm respectively.
D E S C R I P T I O N
Diet Induced Obesity Rodent Purified Diet with 
10% Energy From Fat, Dyed Yellow is based on 
AIN-76A Semi-Purified Diet, Rat or Mouse 5800-B. 
See Van Heek et al., J. Clin. Invest. 99:385-390, 
1997, for initial use of lower-fat versions of this 
formula.  Originally manufactured as "D12450B".
Storage conditions are particularly critical to 
TestDiet® products, due to the absence of 
antioxidants or preservative agents.  To provide 
maximum protection against possible changes 
during storage, store in a dry, cool location.  
Storage under refrigeration (2° C) is 
recommended.  Maximum shelf life is six months.  
(If long term studies are involved, storing the diet 
at -20˚ C or colder may prolong shelf life.)  Be 
F E E D I N G   D I R E C T I O N S
Feed ad libitum.  Plenty of fresh, clean water 
should be available at all times.






Perishable - store properly upon receipt.
For laboratory animal use only; NOT for human 
consumption.
w w w . t e s t d i e t .  c o m 
DIO Rodent Purified Diet w/10% Energy From Fat - Yellow
Cholesterol, ppm 18
58Y2
Product Forms Available* Catalog #
*Other Forms Available On Re
Phosphorus (available), % 0.43
Protein 18.3






Linoleic Acid, % 1.39
Linolenic Acid, % 0.19
Arachidonic Acid, % 0.00
Omega-3 Fatty Acids, % 0.19
Total Saturated Fatty A 1.14
Total Monounsaturated 
Fatty Acids, % 1.30
Glycine, % 0.37
Serine, % 1.05
Aspartic Acid, % 1.22




Polyunsaturated Fatty Acids, % 1.59
Sucrose 33.1290
Dextrin 29.8560









DIO Mineral Mix 0.9480
AIN-76A Vitamin Mix 0.9480
Calcium Carbonate 0.5210
L-Cystine 0.2840
Choline Bitartrate 0.1900
Yellow Dye 0.0500
581241/2" Pellet
568341/2" Pellet, Irradiated
1810727Meal
1810728Meal, Irradiated
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